Evidence map›Paper›PMID 31001343›Full record

ArticleStem cells international2019

Noninvasive Monitoring of Allogeneic Stem Cell Delivery with Dual-Modality Imaging-Visible Microcapsules in a Rabbit Model of Peripheral Arterial Disease.

Yingli Fu, Clifford R Weiss, Dorota A Kedziorek, Yibin Xie, Ellen Tully, Steven M Shea, Meiyappan Solaiyappan, Tina Ehtiati, Kathleen Gabrielson, Frank H Wacker and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Yingli FuRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0003-1516-1854
Clifford R WeissRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA.
Dorota A KedziorekRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA.
Yibin XieRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0002-0333-567X
Ellen TullyRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA.
Steven M SheaSiemens Corporation, Corporate Technology, Baltimore, MD, USA.
Meiyappan SolaiyappanRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA.
Tina EhtiatiSiemens Corporation, Corporate Technology, Baltimore, MD, USA.
Kathleen GabrielsonDepartment of Molecular & Comparative Pathobiology, Johns Hopkins University, Baltimore, MD, USA.
Frank H WackerDepartment of Radiology, Hannover Medical School, Hannover, Germany.
Jeff W M BulteRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA.
Dara L KraitchmanRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA.
Johns Hopkins University · USSiemens Healthcare (United States) · USMedizinische Hochschule Hannover · DE

Funding

Imaging Cardiac Regeneration with Mesenchymal Stem CellsR01HL073223 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI KRAITCHMAN, DARA L · 2003 to 2006
$2.2M
X-ray & MR-visible Microencapsulation of Allogeneic Arteriogenic Cell TherapeuticR33HL089029 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI KRAITCHMAN, DARA L · 2009 to 2011
$2.1M
X-ray & MR-visible Microencapsulation of Allogeneic Arteriogenic Cell TherapeuticR21HL089029 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI KRAITCHMAN, DARA L · 2007 to 2008
$814k
NHLBI NIH HHS R01 HL073223NHLBI NIH HHS R21 HL089029NHLBI NIH HHS R33 HL089029
6 · The paper itself

Abstract

Stem cell therapies, although promising for treating peripheral arterial disease (PAD), often suffer from low engraftment rates and the inability to confirm the delivery success and track cell distribution and engraftment. Stem cell microencapsulation combined with imaging contrast agents may provide a means to simultaneously enhance cell survival and enable cell tracking with noninvasive imaging. Here, we have evaluated a novel MRI- and X-ray-visible microcapsule formulation for allogeneic mesenchymal stem cell (MSC) delivery and tracking in a large animal model. Bone marrow-derived MSCs from male New Zealand White rabbits were encapsulated using a modified cell encapsulation method to incorporate a dual-modality imaging contrast agent, perfluorooctyl bromide (PFOB). PFOB microcapsules (PFOBCaps) were then transplanted into the medial thigh of normal or PAD female rabbits.

Identifiers

PMID31001343
PMCPMC6437732
OpenAlexW2922046430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.